AM Squared Ltd Purchases 1,200 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

AM Squared Ltd raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 600.0% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,400 shares of the biotechnology company’s stock after purchasing an additional 1,200 shares during the quarter. Sarepta Therapeutics accounts for approximately 0.4% of AM Squared Ltd’s holdings, making the stock its 20th biggest position. AM Squared Ltd’s holdings in Sarepta Therapeutics were worth $175,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the company. Capital International Investors grew its stake in shares of Sarepta Therapeutics by 1.6% during the 1st quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after purchasing an additional 76,032 shares during the period. Farallon Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock valued at $317,630,000 after purchasing an additional 1,243,427 shares during the period. Thrivent Financial for Lutherans grew its stake in shares of Sarepta Therapeutics by 6.3% during the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock valued at $101,858,000 after purchasing an additional 37,940 shares during the period. Jacobs Levy Equity Management Inc. grew its stake in shares of Sarepta Therapeutics by 26.3% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company’s stock valued at $75,040,000 after purchasing an additional 120,535 shares during the period. Finally, abrdn plc grew its stake in shares of Sarepta Therapeutics by 30.7% during the 3rd quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock valued at $53,935,000 after purchasing an additional 101,253 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

SRPT has been the subject of a number of recent research reports. UBS Group boosted their price target on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. William Blair raised Sarepta Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Citigroup lowered their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Barclays lowered their price objective on Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Finally, Raymond James reaffirmed an “outperform” rating and set a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, October 10th. One investment analyst has rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Buy” and an average target price of $181.33.

Sarepta Therapeutics Stock Down 4.2 %

Shares of SRPT opened at $104.54 on Friday. The stock has a market capitalization of $9.99 billion, a price-to-earnings ratio of 83.63 and a beta of 0.81. Sarepta Therapeutics, Inc. has a 1 year low of $78.67 and a 1 year high of $173.25. The business’s 50 day simple moving average is $123.72 and its 200-day simple moving average is $132.36. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03.

Insider Transactions at Sarepta Therapeutics

In other news, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. The trade was a 14.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.